Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003153231 | Lung | MIAC | actin cytoskeleton reorganization | 17/967 | 107/18723 | 3.31e-05 | 1.91e-03 | 17 |
GO:003133432 | Lung | MIAC | positive regulation of protein-containing complex assembly | 28/967 | 237/18723 | 3.91e-05 | 2.08e-03 | 28 |
GO:003295632 | Lung | MIAC | regulation of actin cytoskeleton organization | 37/967 | 358/18723 | 4.85e-05 | 2.49e-03 | 37 |
GO:003227323 | Lung | MIAC | positive regulation of protein polymerization | 19/967 | 138/18723 | 8.89e-05 | 3.93e-03 | 19 |
GO:190290523 | Lung | MIAC | positive regulation of supramolecular fiber organization | 22/967 | 209/18723 | 1.23e-03 | 2.31e-02 | 22 |
GO:003083323 | Lung | MIAC | regulation of actin filament polymerization | 19/967 | 172/18723 | 1.47e-03 | 2.55e-02 | 19 |
GO:00514958 | Lung | MIAC | positive regulation of cytoskeleton organization | 23/967 | 226/18723 | 1.51e-03 | 2.61e-02 | 23 |
GO:003004113 | Lung | MIAC | actin filament polymerization | 20/967 | 191/18723 | 2.13e-03 | 3.33e-02 | 20 |
GO:003286831 | Lung | MIAC | response to insulin | 25/967 | 264/18723 | 2.62e-03 | 3.71e-02 | 25 |
GO:004343423 | Lung | MIAC | response to peptide hormone | 35/967 | 414/18723 | 2.97e-03 | 4.00e-02 | 35 |
GO:00080648 | Lung | MIAC | regulation of actin polymerization or depolymerization | 19/967 | 188/18723 | 4.03e-03 | 4.84e-02 | 19 |
GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
GO:005149518 | Oral cavity | OSCC | positive regulation of cytoskeleton organization | 135/7305 | 226/18723 | 1.98e-10 | 5.66e-09 | 135 |
GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
GO:003227319 | Oral cavity | OSCC | positive regulation of protein polymerization | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513025 | Cervix | HSIL_HPV | Pathogenic Escherichia coli infection | 28/459 | 197/8465 | 2.36e-06 | 4.61e-05 | 3.73e-05 | 28 |
hsa0513035 | Cervix | HSIL_HPV | Pathogenic Escherichia coli infection | 28/459 | 197/8465 | 2.36e-06 | 4.61e-05 | 3.73e-05 | 28 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051302 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051303 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051304 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051305 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa051309 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa0513010 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513011 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0513036 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0513039 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
hsa05130115 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BAIAP2L1 | SNV | Missense_Mutation | novel | c.1051N>G | p.Thr351Ala | p.T351A | Q9UHR4 | protein_coding | tolerated(0.78) | possibly_damaging(0.469) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
BAIAP2L1 | SNV | Missense_Mutation | rs775381596 | c.601T>C | p.Cys201Arg | p.C201R | Q9UHR4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BAIAP2L1 | SNV | Missense_Mutation | | c.506N>G | p.Ser169Cys | p.S169C | Q9UHR4 | protein_coding | deleterious(0.02) | benign(0.28) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BAIAP2L1 | SNV | Missense_Mutation | rs140166928 | c.452N>A | p.Arg151Gln | p.R151Q | Q9UHR4 | protein_coding | deleterious(0.03) | benign(0.046) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BAIAP2L1 | insertion | Nonsense_Mutation | novel | c.510_511insGCAACACATGTCACATTTCCTTTCCTTTGTTTTAAATTATGA | p.Arg170_Gln171insAlaThrHisValThrPheProPheLeuCysPheLysLeuTer | p.R170_Q171insATHVTFPFLCFKL* | Q9UHR4 | protein_coding | | | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
BAIAP2L1 | deletion | Frame_Shift_Del | novel | c.1148delN | p.His383ProfsTer26 | p.H383Pfs*26 | Q9UHR4 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
BAIAP2L1 | SNV | Missense_Mutation | novel | c.986N>T | p.Ser329Leu | p.S329L | Q9UHR4 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BAIAP2L1 | SNV | Missense_Mutation | novel | c.1041N>G | p.Ile347Met | p.I347M | Q9UHR4 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
BAIAP2L1 | SNV | Missense_Mutation | rs202012767 | c.127N>A | p.Ala43Thr | p.A43T | Q9UHR4 | protein_coding | deleterious(0.04) | benign(0.116) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
BAIAP2L1 | SNV | Missense_Mutation | | c.842N>T | p.Ser281Leu | p.S281L | Q9UHR4 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |